Sign in

    Arrowhead Pharmaceuticals Inc (ARWR)

    Q3 2024 Earnings Summary

    Reported on Apr 1, 2025 (After Market Close)
    Pre-Earnings Price$25.85Last close (Aug 8, 2024)
    Post-Earnings Price$25.00Open (Aug 9, 2024)
    Price Change
    $-0.85(-3.29%)

    What went well

    • Plozasiran achieved statistically significant reductions in acute pancreatitis events in FCS patients, which differentiates it from competitors and may lead to a strong product label; detailed data will be presented at the ESC meeting.
    • The company expects to release Phase I data from the ARO-CFB program later this year, exploring additional indications such as IgA nephropathy, showcasing pipeline progress and expansion into new therapeutic areas.
    • Secured favorable long-term non-dilutive financing with an attractive 7-year term and no regular coupon payments, strengthening the balance sheet and supporting continued development and commercialization without significant dilution.

    What went wrong

    • The company's R&D expenses have significantly increased, with a $50 million sequential increase this quarter, and expenses are expected to continue increasing into next year, potentially impacting profitability.
    • There is uncertainty regarding the timing of future partnerships and commercial collaborations, which could affect the company's growth and financing plans. The CEO stated they cannot predict the timing on partnerships.
    • The newly announced $500 million credit facility includes a high implied interest rate of 15%, and repayment terms are tied to future cash inflows, which may put pressure on future cash flows and could be costly if expected milestones are delayed or not achieved.

    Q&A Summary

    1. Financing Deal Details
      Q: Explain the terms of the new credit facility.
      A: The company announced a $500 million senior secured credit facility with Sixth Street, including $400 million funded at close and an additional $100 million available at Arrowhead's option. The 7-year term has no scheduled amortization payments or regular cash coupon interest, providing flexibility to fund operations until substantial revenue from plozasiran is expected. This non-dilutive financing is favorable compared to costly equity capital.

    2. Plozasiran NDA Timeline
      Q: When will the plozasiran NDA be filed?
      A: They are in the pre-submission phase and aim to file the NDA for plozasiran by year-end 2024, as previously guided. Preparations include writing and an upcoming pre-NDA meeting with the FDA.

    3. Partnerships and Commercialization
      Q: Will you announce a commercialization partner in 2024?
      A: While actively engaging with potential partners, they cannot predict the timing of any announcements. Partnerships are a priority, but no specific timeline is provided.

    4. ARO-CFB Data Release
      Q: Are you still releasing Phase I ARO-CFB data this year?
      A: Yes, they expect to release data from the ARO-CFB program later this year, including studies in healthy volunteers and patients with IgA nephropathy.

    5. Muscle Programs Data
      Q: When can we expect data from muscle programs?
      A: They have not provided guidance on timing. These early programs are progressing, but they do not expect to have data this year. Results may come next year, depending on progress.

    6. ARO-RAGE Phase II Plans
      Q: What's the status of ARO-RAGE Phase II initiation in asthma?
      A: They are developing Phase II plans but are still working out details like patient selection and treatment duration. No guidance on additional data timing is provided.

    7. FCS Label and Payer Access
      Q: Will payers restrict FCS treatment to genetic cases?
      A: Since patients appear clinically similar regardless of genetics, they expect payers to follow the FDA label. Assuming approval, payers will likely cover patients matching the study criteria, both genetically confirmed and clinically diagnosed.

    8. Increased R&D Expenses
      Q: Explain the $50 million R&D increase this quarter.
      A: R&D expenses increased as assets advanced to later stages. Expenses are expected to continue rising into next year. They are budgeting now and will provide more guidance at the next earnings call.

    9. Credit Facility Repayment Terms
      Q: What are the repayment terms for the credit facility?
      A: Repayment depends on the asset involved. The structure is customized, with different payback terms for different assets. Some transactions may require no repayment portion.

    10. Dimers and Neuromuscular Programs
      Q: When could dimers enter the clinic?
      A: They expect their first dimer, targeting PCSK9 and APOC3, to enter the clinic next year. Initially focusing on delivery to hepatocytes, with plans to expand to other tissues as technology matures.

    Related Publications